This article was originally published in The Gray Sheet
Executive SummaryBiotech firm says its initial public offering of 4 mil. shares at $9 each has been postponed due to market conditions after the planned offering price was recently lowered from $12-14 per share. The IPO is now anticipated to take place later this year. The Issaquah, Washington-based biopharmaceutical firm markets through its Bartels subsidiary a line of in vitro diagnostic products for confirmation of viral and bacterial diseases and is developing additional diagnostics for detecting and monitoring various cancers, AIDS and heart disease. The company also is focusing on development and commercialization of cancer vaccines and immunotherapeutic products for cancer and infectious diseases. Proceeds from the offering will go primarily toward drug development, debt repayment, R&D, working capital and general corporate purposes. Underwriters for the offering are Donaldson Lufkin & Jenrette and Piper Jaffray
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.